Results 101 to 110 of about 902 (167)

SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu   +6 more
wiley   +1 more source

The Role of Neuropeptide Y in Dental Pulp: Balancing Neurogenic Inflammation and Pain Modulation

open access: yesInternational Endodontic Journal, EarlyView.
ABSTRACT Background Dental pulp is a densely innervated, low‐compliance tissue in which neurogenic inflammation can rapidly escalate into oedema, raised intrapulpal pressure, microvascular compromise, and pain. While Substance P (SP) and Calcitonin gene‐related peptide (CGRP) are well‐established drivers of pulp vasodilation, the Neuroopeptide Y (NPY ...
Javier Caviedes‐Bucheli   +3 more
wiley   +1 more source

From biology to biotechnology: Host‐regulation factors from parasitoid wasps are a source of bioactive molecules with translational potential

open access: yesInsect Molecular Biology, EarlyView.
Parasitoid wasps deploy maternal and embryonic factors to reprogramme host physiology. Venom, calyx fluid, polydnaviruses, teratocytes and larval secretions act in a coordinated, compartmentalised manner. Host‐regulation factors are promising sources of insecticidal, antimicrobial and bioinspired translational molecules.
Ciro Pedro G. Pinto   +2 more
wiley   +1 more source

Immune Consequences of Metabolic Syndrome and Its Treatment: A Cytokine Perspective

open access: yesImmunology, EarlyView.
Peripheral blood mononuclear cells (PBMCs) from individuals with metabolic syndrome (MetS) who were not using glucose‐and/or lipid lowering medication (GLLM) exhibited a broader cytokine production profile after in vitro antigen‐specific stimulation than PBMCs from individuals with MetS using such medications and from healthy donors.
Isabela Ghetti Macedo Isaac   +7 more
wiley   +1 more source

Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors?

open access: yesJournal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction Sodium‐glucose cotransporter‐2 inhibitors (SGLT2Is) are recommended in Japan for patients with cardiovascular disease (CVD), heart failure (HF), or chronic kidney disease (CKD) due to their organ‐protective effects, leading to increased use in high‐risk populations.
Takuma Koinuma   +2 more
wiley   +1 more source

Associations of skeletal muscle mass and strength with arterial stiffness in type 2 diabetes

open access: yesJournal of Diabetes Investigation, EarlyView.
Lower skeletal muscle mass and lower handgrip strength were associated with higher arterial stiffness in individuals with type 2 diabetes. Assessment of both parameters may provide complementary information regarding vascular risk. ABSTRACT Sarcopenia is prevalent in people with type 2 diabetes mellitus (T2DM) and may contribute to increased ...
Naoki Koike   +10 more
wiley   +1 more source

Comparative Effectiveness of GLP‐1RAs, SGLT2is and DPP4is for Cardiovascular Outcomes in Type 2 Diabetes: An Empirically Calibrated Target Trial Emulation Study

open access: yes
Diabetes, Obesity and Metabolism, EarlyView.
Bingyu Zhang   +9 more
wiley   +1 more source

Waist‐to‐height ratio and renal dysfunction as independent correlates of low handgrip strength in patients with type 2 diabetes

open access: yesJournal of Diabetes Investigation, EarlyView.
In 1,468 patients with type 2 diabetes, central obesity (WHtR >0.5) neutralizes the protective effects of higher BMI on muscle strength. Concurrently, visceral adiposity and CKD impose an additive threat, maximizing low handgrip strength risk (aOR = 1.74). Combining WHtR and renal tracking optimizes clinical sarcopenia screening.
Shing‐Hua Chen   +4 more
wiley   +1 more source

Effect of Sotagliflozin on Kidney Function and Cardio‐Kidney‐Metabolic Parameters Across Baseline eGFR Subgroups in Patients With Type 2 Diabetes and Stage 4 CKD

open access: yes
Diabetes, Obesity and Metabolism, EarlyView.
Vikas S. Sridhar   +4 more
wiley   +1 more source

Clinical characteristics of Sarcopenic obesity in Japanese people with type 2 diabetes: A post hoc analysis of the sub‐cohort iDIAMOND study

open access: yesJournal of Diabetes Investigation, EarlyView.
Among participants aged 40–75 years, sarcopenic obesity was observed in 4.9% of those with T2D and 0.5% of non‐D individuals. Sarcopenic obesity is more prevalent in individuals with T2D and is associated with impaired physical QOL, reduced walking ability, and increased falls.
Hiroyasu Mori   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy